Open access · CC-BY
via OpenAlex
HIGH RESOLUTION SPATIAL PROTEOGENOMICS TO ASSESS TARGET ENGAGEMENT AND COMPARE SENOLYTIC EFFICACY IN THE BRAIN OF TAU TRANSGENIC MICE
Miranda E. Orr, Valentina Rose Garbarino, Timothy Orr
Innovation in Aging · 2024
Abstract
Abstract Tau protein accumulation induces cellular senescence(definition) in Alzheimer’s disease and other tauopathies contributing to dysfunction and disability. Treating tau transgenic mice with pharmacological agents to clear senescent cells, “senolytics(definition),” reduced brain pathology and improved structure and function. We now report results from directly comparing the previously used senolytic therapy, dasatinib plus quercetin (D+Q), to fisetin (FIS), a senolytic with a potentially favorable side-effect profile. Fourteen-month-old male and female wild type (WT) and tau transgenic (rTg4510) mice were treated intermittently for 12 weeks with D+Q, FIS or vehicle by oral gavage. Physical and behavioral outcomes were measured before and after treatment, and we utilized spatial proteogenomics for high-resolution target engagement. In vivo assessments included assays for exploratory behavior, cognition, stereotypic behavior, physical performance and frailty. Genotype- and sex-specific treatment effects will be discussed. Both senolytic treatments were equally protective against neurodegeneration as evidenced by smaller lateral ventricle size in senolytic treated rTg4510s compared to those vehicle treated. GeoMx digital spatial profiling and CosMx spatial molecular imaging data indicate treatment-specific effects with a genotype interaction. In general D+Q exerted a greater effect on tau neuropathology in rTg4510 mice; other treatment-specific differences across cell types and brain regions will be presented. Overall our data suggest that tailoring senolytic therapies to specific individuals in the future based on sex and disease state may provide the most benefit as we continue to translate this promising therapy to clinical use.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1093/geroni/igae098.1144
- Canonical
- link ↗
- Fetched
- 2026-10-09 MST
Cite this
APA
Orr, M.E., Garbarino, V.R., & Orr, T. (2024). HIGH RESOLUTION SPATIAL PROTEOGENOMICS TO ASSESS TARGET ENGAGEMENT AND COMPARE SENOLYTIC EFFICACY IN THE BRAIN OF TAU TRANSGENIC MICE. <em>Innovation in Aging</em>. https://doi.org/10.1093/geroni/igae098.1144
Vancouver
Orr ME, Garbarino VR, Orr T. HIGH RESOLUTION SPATIAL PROTEOGENOMICS TO ASSESS TARGET ENGAGEMENT AND COMPARE SENOLYTIC EFFICACY IN THE BRAIN OF TAU TRANSGENIC MICE. Innovation in Aging. 2024. doi:10.1093/geroni/igae098.1144.
BibTeX
@article{miranda2024HIGHRE,
title = {HIGH RESOLUTION SPATIAL PROTEOGENOMICS TO ASSESS TARGET ENGAGEMENT AND COMPARE SENOLYTIC EFFICACY IN THE BRAIN OF TAU TRANSGENIC MICE},
author = {Miranda E. Orr and Valentina Rose Garbarino and Timothy Orr},
journal = {Innovation in Aging},
year = {2024},
doi = {10.1093/geroni/igae098.1144},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Alzheimer s & Dementia 2025
Open access · CC-BY
Head‐to‐head comparison of two senolytic therapies in a mouse model of tauopathy
Alzheimer s & Dementia 2020
Open access · OA
A head‐to‐head comparison between senolytic therapies, dasatinib plus quercetin and fisetin, indicates sex‐ and genotype‐specific differences in translationally relevant outcomes
Aging Cell 2025
Open access · CC-BY
Intermittent Supplementation With Fisetin Improves Physical Function and Decreases Cellular Senescence in Skeletal Muscle With Aging: A Comparison to Genetic Clearance of Senescent Cells and Synthetic Senolytic Approaches
The Journal of Prevention of Alzheimer s Disease 2021
Open access · CC-BY
Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD): A Pilot Clinical Trial
The Journal of Prevention of Alzheimer s Disease 2023
Open access · CC-BY
Translating the Biology of Aging into New Therapeutics for Alzheimer's Disease: Senolytics
Journal of Alzheimer s Disease 2024
Preprint · OA